{"doi":"10.1002/ajh.27283","title":"Benefit of axicabtagene ciloleucel versus chemoimmunotherapy in older patients and/or patients with poor <scp>ECOG</scp> performance status with relapsed or refractory large B‐cell lymphoma after 2 or more lines of prior therapy","abstract":"Axicabtagene ciloleucel (axi-cel) in trials has demonstrated favorable efficacy compared with historical controls after ≥2 lines of therapy for the treatment of relapsed or refractory (R/R) large B cell lymphoma (LBCL). Herein, we compared the real-world effectiveness of axi-cel with efficacy and effectiveness of chemoimmunotherapy (CIT) in patients aged ≥65 years and patients with Eastern Cooperative Oncology Group performance status (ECOG PS) of 2. A total of 1146 patients treated with commercial axi-cel for R/R LBCL with ≥2 lines of prior therapy were included from the Center for International Blood and Marrow Transplantation Research prospective observational study, and 469 patients treated with CIT for R/R LBCL after ≥2 lines of prior therapy were included from SCHOLAR-1 (an international, multicohort, retrospective study). After propensity score matching, at a median follow-up of 24 months for patients receiving axi-cel and 60 months for patients receiving CIT, 12-month overall survival rates were 62% and 28%, respectively (hazard ratio, 0.30 [95% CI, 0.24-0.37]). Objective response rate (ORR) was 76% (complete response [CR] rate 58%) in patients receiving axi-cel versus 28% (CR rate 16%) for those receiving CIT. A 57% difference in ORR (55% difference in CR rate) favoring axi-cel over CIT was observed among patients aged ≥65 years. Increased magnitude of benefit in response rates for axi-cel versus CIT was also observed among patients with ECOG PS = 2. These findings further support the broader use of axi-cel in older patients and patients with ECOG PS = 2 with R/R LBCL.","journal":"American Journal of Hematology","year":2024,"id":465100,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":4,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9526,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2024-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":646454,"name":"Hailin Wang","orcid":"0000-0002-1843-999X","position":1,"is_corresponding":false},{"id":284115,"name":"Zhen‐Huan Hu","orcid":"0000-0002-3303-8991","position":2,"is_corresponding":false},{"id":11097,"name":"Frederick L. Locke","orcid":"0000-0001-9063-6691","position":3,"is_corresponding":false},{"id":11104,"name":"Tanya Siddiqi","orcid":"0000-0001-5292-8298","position":4,"is_corresponding":false},{"id":11101,"name":"Caron A. Jacobson","orcid":"0000-0002-0180-0654","position":5,"is_corresponding":false},{"id":247184,"name":"Sairah Ahmed","orcid":"0000-0001-7302-8299","position":6,"is_corresponding":false},{"id":11100,"name":"David B. Miklos","orcid":"0000-0003-0717-4305","position":7,"is_corresponding":false},{"id":11105,"name":"Yi Lin","orcid":"0000-0002-1556-6416","position":8,"is_corresponding":false},{"id":11111,"name":"Brian T. Hill","orcid":"0000-0001-8781-3327","position":9,"is_corresponding":false},{"id":11121,"name":"Armin Ghobadi","orcid":"0000-0001-8848-8474","position":10,"is_corresponding":false},{"id":11096,"name":"Sattva S. Neelapu","orcid":"0000-0003-1045-4914","position":11,"is_corresponding":false},{"id":11119,"name":"Jason R. Westin","orcid":"0000-0002-1824-2337","position":12,"is_corresponding":false},{"id":1296605,"name":"C. Dieyi","orcid":null,"position":13,"is_corresponding":false},{"id":1296606,"name":"Polly Field","orcid":null,"position":14,"is_corresponding":false},{"id":882198,"name":"Harry Miao","orcid":"0009-0003-7480-7405","position":15,"is_corresponding":false},{"id":487745,"name":"Shilpa Shahani","orcid":null,"position":16,"is_corresponding":false},{"id":603236,"name":"Anik R. Patel","orcid":"0000-0001-9091-8904","position":17,"is_corresponding":false},{"id":133332,"name":"Clare Spooner","orcid":null,"position":18,"is_corresponding":false},{"id":1296607,"name":"Christine Fu","orcid":null,"position":19,"is_corresponding":false},{"id":1296608,"name":"David Muramoto","orcid":null,"position":20,"is_corresponding":false},{"id":806763,"name":"Hairong Xu","orcid":"0000-0001-9013-996X","position":21,"is_corresponding":false},{"id":122967,"name":"Marcelo C. Pasquini","orcid":"0000-0003-1579-2293","position":22,"is_corresponding":false},{"id":108399,"name":"Matthew A. Lunning","orcid":"0000-0002-2761-7612","position":0,"is_corresponding":true}],"reference_count":26,"raw_metadata":null,"created_at":"2026-07-19T02:04:46.201722Z","pmid":"38504387","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}